Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo observacional, prospectivo e multicêntrico de longo prazo para coletar em uma população do mundo real dados sobre o padrão de tratamento de secukinumAb em pacientes adultos com hidradenite supurativa moderada a grave. (ANIMA)

13 de novembro de 2026 atualizado por: Novartis Pharmaceuticals

Estudo observacional, prospectivo e multicêntrico de longo prazo para coletar dados em uma população do mundo real sobre o padrão de tratamento de secukinumAb em pacientes adultos com hidradenite supurativa (HS) moderada a grave (ANIMA)

The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.

Visão geral do estudo

Status

Ativo, não recrutando

Intervenção / Tratamento

Descrição detalhada

The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.

In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.

Tipo de estudo

Observacional

Inscrição (Real)

436

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Aachen, Alemanha, 52064
        • Novartis Investigative Site
      • Ahaus, Alemanha, 48683
        • Novartis Investigative Site
      • Annaberg-Buchholz, Alemanha, 09456
        • Novartis Investigative Site
      • Bad Steben, Alemanha, 95138
        • Novartis Investigative Site
      • Baden-Baden, Alemanha, 76530
        • Novartis Investigative Site
      • Berlin, Alemanha, 12159
        • Novartis Investigative Site
      • Berlin, Alemanha, 13595
        • Novartis Investigative Site
      • Bielefeld, Alemanha, 33647
        • Novartis Investigative Site
      • Bochum, Alemanha, 44791
        • Novartis Investigative Site
      • Bonn, Alemanha, 53105
        • Novartis Investigative Site
      • Brandenburg, Alemanha, 14776
        • Novartis Investigative Site
      • Bremen, Alemanha, 28359
        • Novartis Investigative Site
      • Buxtehude, Alemanha, 21614
        • Novartis Investigative Site
      • Bückeburg, Alemanha, 31675
        • Novartis Investigative Site
      • Chemnitz, Alemanha, 09117
        • Novartis Investigative Site
      • Chemnitz, Alemanha, 09113
        • Novartis Investigative Site
      • Cologne, Alemanha, 51065
        • Novartis Investigative Site
      • Delitzsch, Alemanha, 04509
        • Novartis Investigative Site
      • Dessau, Alemanha, 06847
        • Novartis Investigative Site
      • Dorsten, Alemanha, 46282
        • Novartis Investigative Site
      • Dortmund, Alemanha, 44137
        • Novartis Investigative Site
      • Dresden, Alemanha, 01309
        • Novartis Investigative Site
      • Düren, Alemanha, 52349
        • Novartis Investigative Site
      • Emsdetten, Alemanha, 48282
        • Novartis Investigative Site
      • Erlangen, Alemanha, 91054
        • Novartis Investigative Site
      • Falkenberg, Alemanha, 04895
        • Novartis Investigative Site
      • Falkensee, Alemanha, 14612
        • Novartis Investigative Site
      • Freising, Alemanha, 85354
        • Novartis Investigative Site
      • Geilenkirchen, Alemanha, 52511
        • Novartis Investigative Site
      • Gera, Alemanha, 07548
        • Novartis Investigative Site
      • Gernsbach, Alemanha, 76593
        • Novartis Investigative Site
      • Gladbeck, Alemanha, 45964
        • Novartis Investigative Site
      • Großenhain, Alemanha, 01558
        • Novartis Investigative Site
      • Hamburg, Alemanha, 20246
        • Novartis Investigative Site
      • Hamburg, Alemanha, 22143
        • Novartis Investigative Site
      • Hanover, Alemanha, 30159
        • Novartis Investigative Site
      • Haslach im Kinzigtal, Alemanha, 77716
        • Novartis Investigative Site
      • Hofgeismar, Alemanha, 34369
        • Novartis Investigative Site
      • Jena, Alemanha, 07743
        • Novartis Investigative Site
      • Jülich, Alemanha, 52428
        • Novartis Investigative Site
      • Karlsruhe, Alemanha, 76133
        • Novartis Investigative Site
      • Kempen, Alemanha, 47906
        • Novartis Investigative Site
      • Lübeck, Alemanha, 23538
        • Novartis Investigative Site
      • Magdeburg, Alemanha, 39120
        • Novartis Investigative Site
      • Magdeburg, Alemanha, 39104
        • Novartis Investigative Site
      • Mainz, Alemanha, 55116
        • Novartis Investigative Site
      • Marburg, Alemanha, 35043
        • Novartis Investigative Site
      • Minden, Alemanha, 32429
        • Novartis Investigative Site
      • Mönchengladbach, Alemanha, 41063
        • Novartis Investigative Site
      • Neu Wulmstorf, Alemanha, 21629
        • Novartis Investigative Site
      • Nuremberg, Alemanha, 90419
        • Novartis Investigative Site
      • Oberasbach, Alemanha, 90522
        • Novartis Investigative Site
      • Oelde, Alemanha, 59302
        • Novartis Investigative Site
      • Peitz, Alemanha, 03185
        • Novartis Investigative Site
      • Potsdam, Alemanha, 14469
        • Novartis Investigative Site
      • Remscheid, Alemanha, 42897
        • Novartis Investigative Site
      • Selters, Alemanha, 56242
        • Novartis Investigative Site
      • Simmern, Alemanha, 55469
        • Novartis Investigative Site
      • Soest, Alemanha, 59494
        • Novartis Investigative Site
      • Stolberg, Alemanha, 52222
        • Novartis Investigative Site
      • Unna, Alemanha, 59423
        • Novartis Investigative Site
      • Wittlich, Alemanha, 54316
        • Novartis Investigative Site
      • Wuppertal, Alemanha, 42103
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Alemanha, 79068
        • Novartis Investigative Site
      • Rheinstetten, Baden-Wurttemberg, Alemanha, 76287
        • Novartis Investigative Site
    • Bavaria
      • Haßfurt, Bavaria, Alemanha, 97437
        • Novartis Investigative Site
      • Kulmbach, Bavaria, Alemanha, 95326
        • Novartis Investigative Site
      • Lauf an der Pegnitz, Bavaria, Alemanha, 91207
        • Novartis Investigative Site
      • Nuremberg, Bavaria, Alemanha, 90402
        • Novartis Investigative Site
    • Brandenburg
      • Panketal, Brandenburg, Alemanha, 16341
        • Novartis Investigative Site
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, Alemanha, 22549
        • Novartis Investigative Site
    • Lower Saxony
      • Lingen, Lower Saxony, Alemanha, 49809
        • Novartis Investigative Site
    • Mecklenburg-Vorpommern
      • Bergen auf Rügen, Mecklenburg-Vorpommern, Alemanha, 18528
        • Novartis Investigative Site
      • Kröpelin, Mecklenburg-Vorpommern, Alemanha, 18236
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Krefeld, North Rhine-Westphalia, Alemanha, 47798
        • Novartis Investigative Site
    • Rhineland-Palatinate
      • Mainz, Rhineland-Palatinate, Alemanha, 55128
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, Alemanha, 01307
        • Novartis Investigative Site
      • Leipzig, Saxony, Alemanha, 04207
        • Novartis Investigative Site
      • Leipzig, Saxony, Alemanha, 04289
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Wittenberg, Saxony-Anhalt, Alemanha, 06886
        • Novartis Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 99 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

Descrição

Inclusion Criteria:

Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:

  1. Patients who provide written informed consent to participate in the study
  2. Male and female patients with ≥18 years of age
  3. Diagnosis of clinically unequivocal moderate to severe HS
  4. Patients for whom a therapy with secukinumab is medically indicated
  5. Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
  6. Treatment with secukinumab according to the latest version of SmPC
  7. Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit

Exclusion Criteria:

Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:

  1. Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
  2. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
  3. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
  4. Previous exposure to IL-17 inhibitors
  5. For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
secukinumab

Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of patients receiving up-titration
Prazo: Up to 24 months

Proportion of patients receiving up-titration (q4w-to-q2w)

Up to 24 months
Proportion of patients receiving down-titration
Prazo: Up to 24 months

Proportion of patients receiving down-titration (q2w-to-q4w)

Up to 24 months
Time to up-titration and down-titration
Prazo: Up to 2 years

Time to up-titration and down-titration

Up to 2 years
Duration of q4w treatment with secukinumab after dose reduction
Prazo: Up to 2 years

Duration of q4w treatment with secukinumab after dose reduction

Up to 2 years
Proportion of patients who receive more than one up-and/or down titration
Prazo: Up to 24 months

Proportion of patients who receive more than one up-and/or down titration

Up to 24 months
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Prazo: Up to 2 years

Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab

Up to 2 years
Number and type of surgical interventions
Prazo: Up to 2 years

Number and type of surgical interventions

  • minor and major surgical excision;
  • inpatient, outpatient
Up to 2 years
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Prazo: Up to 24 months

The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity.

HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

Up to 24 months
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
Prazo: Up to 24 months

The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity.

HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

Up to 24 months
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Prazo: Up to 24 months

The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school.

Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

Up to 24 months
Mean reduction of Abscesses and inflammatory nodules (AN) count
Prazo: Up to 24 months

Mean reduction of Abscesses and inflammatory nodules (AN) count

Up to 24 months
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
Prazo: Up to 24 months

The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form.

Up to 24 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

10 de agosto de 2023

Conclusão Primária (Estimado)

31 de março de 2027

Conclusão do estudo (Estimado)

31 de março de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

16 de junho de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de junho de 2023

Primeira postagem (Real)

28 de junho de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever